Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SRG-514 in Triple Negative Breast Cancer Undergoing Breast-Conserving Surgery
NCT07723469Phase 3Not yet recruiting
- Sponsor
- SURGE Therapeutics
- Start
- Oct 2026
- Primary completion
- Oct 2034
- Countries
- 1
01
Overview
A Phase 3 trial of SRG-514 in triple-negative breast cancer (TNBC), sponsored by SURGE Therapeutics. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
SRG-514
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07723469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07723469.